At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MATCH Treatment Subprotocol K1: Phase 2 Study of JNJ-42756493 (Erdafitinib) in Patients With Tumors With FGFR Amplifications
In Brief
A Phase 2 clinical trial evaluating Biopsy Procedure, Biospecimen Collection, and 3 other interventions for Advanced Lymphoma and 4 related conditions. Active but no longer recruiting, targeting 35 participants across 1 site.
Detailed Summary
This phase II MATCH treatment trial tests how well JNJ-42756493 (erdafitinib) works in treating patients with tumors that have more copies of the FGFR gene than is normal (amplification). Erdafitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal FGFR protein that signals cancer cells to multiply.
Study Details
Timeline
Interventions
Undergo tumor biopsy
Undergo blood sample collection
Undergo CT
Given PO
Undergo MRI